BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhao L, Zhao J, Zhong K, Tong A, Jia D. Targeted protein degradation: mechanisms, strategies and application. Sig Transduct Target Ther 2022;7. [DOI: 10.1038/s41392-022-00966-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Li S, Chen T, Liu J, Zhang H, Li J, Wang Z, Shang G. PROTACs: Novel tools for improving immunotherapy in cancer. Cancer Lett 2023;560:216128. [PMID: 36933781 DOI: 10.1016/j.canlet.2023.216128] [Reference Citation Analysis]
2 Pan Y, Xia H, He Y, Zeng S, Shen Z, Huang W. The progress of molecules and strategies for the treatment of HBV infection. Front Cell Infect Microbiol 2023;13. [DOI: 10.3389/fcimb.2023.1128807] [Reference Citation Analysis]
3 Lu S, Dai Z, Cui Y, Kong D. Recent Development of Advanced Fluorescent Molecular Probes for Organelle-Targeted Cell Imaging. Biosensors 2023;13:360. [DOI: 10.3390/bios13030360] [Reference Citation Analysis]
4 Zhu H, Wang J, Zhang Q, Pan X, Zhang J. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance. Pharmacol Ther 2023;244:108371. [PMID: 36871783 DOI: 10.1016/j.pharmthera.2023.108371] [Reference Citation Analysis]
5 Kwon J, Kim J, Kim KI. Crosstalk between endoplasmic reticulum stress response and autophagy in human diseases. Anim Cells Syst (Seoul) 2023;27:29-37. [PMID: 36860271 DOI: 10.1080/19768354.2023.2181217] [Reference Citation Analysis]
6 Zhang N, Huang D, Ruan X, Ng AT, Tsu JH, Jiang G, Huang J, Zhan Y, Na R. CRISPR screening reveals gleason score and castration resistance related oncodriver ring finger protein 19 A (RNF19A) in prostate cancer. Drug Resist Updat 2023;67:100912. [PMID: 36623445 DOI: 10.1016/j.drup.2022.100912] [Reference Citation Analysis]
7 Giandomenico SL, Schuman EM. Genetic manipulation and targeted protein degradation in mammalian systems: practical considerations, tips and tricks for discovery research. FEBS Open Bio 2023. [PMID: 36815235 DOI: 10.1002/2211-5463.13581] [Reference Citation Analysis]
8 Li X, Liu Q, Xie X, Peng C, Pang Q, Liu B, Han B. Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research. J Med Chem 2023;66:1700-11. [PMID: 36716420 DOI: 10.1021/acs.jmedchem.2c01712] [Reference Citation Analysis]
9 Chakravarty A, Yang PL. Targeted protein degradation as an antiviral approach. Antiviral Res 2023;210:105480. [PMID: 36567024 DOI: 10.1016/j.antiviral.2022.105480] [Reference Citation Analysis]
10 Horvath RM, Brumme ZL, Sadowski I. Inhibition of the TRIM24 bromodomain reactivates latent HIV-1. Sci Rep 2023;13:556. [PMID: 36631514 DOI: 10.1038/s41598-023-27765-3] [Reference Citation Analysis]
11 Zheng J, He W, Li J, Feng X, Li Y, Cheng B, Zhou Y, Li M, Liu K, Shao X, Zhang J, Li H, Chen L, Fang L. Bifunctional Compounds as Molecular Degraders for Integrin-Facilitated Targeted Protein Degradation. J Am Chem Soc 2022;144:21831-6. [PMID: 36417563 DOI: 10.1021/jacs.2c08367] [Reference Citation Analysis]
12 Salama AKAA, Trkulja MV, Casanova E, Uras IZ. Targeted Protein Degradation: Clinical Advances in the Field of Oncology. Int J Mol Sci 2022;23. [PMID: 36499765 DOI: 10.3390/ijms232315440] [Reference Citation Analysis]
13 VanDyke D, Taylor JD, Kaeo KJ, Hunt J, Spangler JB. Biologics-based degraders - an expanding toolkit for targeted-protein degradation. Curr Opin Biotechnol 2022;78:102807. [PMID: 36179405 DOI: 10.1016/j.copbio.2022.102807] [Reference Citation Analysis]
14 Dai MY, Shi YY, Wang AJ, Liu XL, Liu M, Cai HB. High-potency PD-1/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells. Cell Death Dis 2022;13:924. [PMID: 36333311 DOI: 10.1038/s41419-022-05375-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Pu C, Wang S, Liu L, Feng Z, Zhang H, Gong Q, Sun Y, Guo Y, Li R. Current strategies for improving limitations of proteolysis targeting chimeras. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.107927] [Reference Citation Analysis]
16 Horvath RM, Brumme ZL, Sadowski I. Inhibition of the TRIM24 bromodomain reactivates latent HIV-1.. [DOI: 10.21203/rs.3.rs-2083312/v1] [Reference Citation Analysis]
17 Srivastava R, Fernández-Ginés R, Encinar JA, Cuadrado A, Wells G. The current status and future prospects for therapeutic targeting of KEAP1-NRF2 and β-TrCP-NRF2 interactions in cancer chemoresistance. Free Radic Biol Med 2022:S0891-5849(22)00605-0. [PMID: 36181972 DOI: 10.1016/j.freeradbiomed.2022.09.023] [Reference Citation Analysis]
18 Liu Y, Liu R, Dong J, Xia X, Yang H, Wei S, Fan L, Fang M, Zou Y, Zheng M, Leong KW, Shi B. Targeted Protein Degradation via Nanoparticles.. [DOI: 10.1101/2022.09.21.508905] [Reference Citation Analysis]
19 Wang S, Jiang S, Zheng G, Cho YK. Targeted degradation of microtubule-associated protein tau using an engineered nanobody-E3 ubiquitin ligase adapter fusion.. [DOI: 10.1101/2022.09.01.506229] [Reference Citation Analysis]
20 Zhou X, Zhao F, Xu Y, Guan Y, Yu T, Zhang Y, Duan Y, Zhao Y. A Comprehensive Review of BET-targeting PROTACs for Cancer Therapy. Bioorganic & Medicinal Chemistry 2022. [DOI: 10.1016/j.bmc.2022.117033] [Reference Citation Analysis]
21 Zhang D, Wornow S, Peehl DM, Rankin EB, Brooks JD. The controversial role and therapeutic development of the m6A demethylase FTO in renal cell carcinoma. Transl Oncol 2022;25:101518. [PMID: 36037557 DOI: 10.1016/j.tranon.2022.101518] [Reference Citation Analysis]
22 Kim H, Park J, Kim J. Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway. Biomedicines 2022;10:2100. [DOI: 10.3390/biomedicines10092100] [Reference Citation Analysis]
23 Liu Z, Zhang Y, Xiang Y, Kang X. Small-Molecule PROTACs for Cancer Immunotherapy. Molecules 2022;27:5439. [DOI: 10.3390/molecules27175439] [Reference Citation Analysis]
24 Graham H. The mechanism of action and clinical value of PROTACs: A graphical review. Cell Signal 2022;99:110446. [PMID: 35995302 DOI: 10.1016/j.cellsig.2022.110446] [Reference Citation Analysis]
25 Wang W, He S, Dong G, Sheng C. Nucleic-Acid-Based Targeted Degradation in Drug Discovery. J Med Chem 2022. [PMID: 35916496 DOI: 10.1021/acs.jmedchem.2c00875] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Sasso JM, Tenchov R, Wang D, Johnson LS, Wang X, Zhou QA. Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic. Biochemistry 2023;62:601-23. [PMID: 35856839 DOI: 10.1021/acs.biochem.2c00245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
27 Yan J, Li T, Miao Z, Wang P, Sheng C, Zhuang C. Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation. J Med Chem 2022. [PMID: 35763424 DOI: 10.1021/acs.jmedchem.2c00728] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Horvath RM, Brumme ZL, Sadowski I. Inhibition of the TRIM24 bromodomain reactivates latent HIV-1.. [DOI: 10.1101/2022.06.16.496524] [Reference Citation Analysis]
29 Ding Y, Xing D, Fei Y, Lu B. Emerging degrader technologies engaging lysosomal pathways. Chem Soc Rev 2022;51:8832-8876. [DOI: 10.1039/d2cs00624c] [Cited by in F6Publishing: 1] [Reference Citation Analysis]